CKS2 Promotes the Growth in Non-Small-Cell Lung Cancer by Downregulating Cyclin-Dependent Kinase Inhibitor
Conclusions: Our study suggests that CKS2 could be a biomarker in the progression and prognosis of NSCLC.Pathobiology
Source: Pathobiology - Category: Pathology Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Pathology | Study